Frontlight ResearchEarly access
CompletedNo phase
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma
Key facts
- Who runs it
- Sohag University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 50 people enrolled
- Started
- 1 Sept 2026
- Ended
- 22 Oct 2026
- Type of study
- Observational
- Treatments tested
- Immunohistochemical staining
- Record updated
- 10 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Histologically confirmed meningioma cases. 2) Cases classified according to WHO CNS5 (2021). 3) Tissue blocks with sufficient material. 4) Specimens with sufficient clinical data; -
Who cannot take part
- Tissue blocks with insufficient, destroyed or necrotic material. 2) Specimens with insufficient clinical data; -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma and associate its expression with certain clinical and pathological paramaters as age, sex of the patients, site (right or left and location), size, diagnosis, WHO grade, if there is bone invasion, if there is necrosis and vascular invasion.
The group in the trial
- Participants
Fifty (50) cases of meningioma will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Treatment: Immunohistochemical staining
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 November 2026